Posts

Posted on

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 45,000 shares of the company’s common stock, at a per share exercise price of $3.45, the closing trading price on November 6, and restricted stock units to acquire 22,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company’s board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc. 
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact:

Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
[email protected]

Media:
Sarah Mathieson
Vice President, Communications & Engagement
510-450-3528
[email protected]

Posted on

Maiden Commences Tender Offer to Purchase Preference Shares, Series A, Series C and Series D for an Aggregate Purchase Price of up to $100,000,000

Maiden Commences Tender Offer to Purchase Preference Shares, Series A, Series C and Series D for an Aggregate Purchase Price of up to $100,000,000

PEMBROKE, Bermuda–(BUSINESS WIRE)–
Maiden Holdings, Ltd. (NASDAQ:MHLD) (“Maiden”) announced today the commencement of a cash tender offer (the “Offer”), through its indirect, wholly-owned subsidiary, Maiden Reinsurance Ltd. (the “Company”), to purchase the number of securities listed in the table below (the “Securities”) as can be purchased for an aggregate purchase price of up to $100,000,000 (the “Maximum Aggregate Purchase Amount”).

Series of Securities

CUSIP No. / ISIN

Liquidation Preference

Per Share

Aggregate

Liquidation

Preference

Outstanding

Offer Price

8.250% Non-Cumulative Preference Shares, Series A of Maiden Holdings, Ltd. (“Series A Preference Shares”)

 

G5753U 120 /

BMG5753U1201

$25.00

 

$150,000,000

 

$10.50 per share

7.125% Non-Cumulative Preference Shares, Series C of Maiden Holdings, Ltd. (“Series C Preference Shares”)

 

G5753U 138 /

BMG5753U1383

$25.00

 

$165,000,000

 

$10.50 per share

6.700% Non-Cumulative Preference Shares, Series D of Maiden Holdings, Ltd. (“Series D Preference Shares”)

G5753U 146 /

BMG5753U1466

$25.00

 

$150,000,000

 

$10.50 per share

The consideration for each Series A Preference Share, each Series C Preference Share and each Series D Preference Share tendered and accepted for purchase pursuant to the Offer will equal $10.50 (the “Offer Price”). The Offer Price does not, and will not, include any amount with respect to dividends.

The principal purpose of the Offer is to adjust Maiden’s capital structure to reflect its current operations and the amount of capital required to operate both Maiden and the Company. Maiden’s board of directors has not declared or paid dividends on the Securities since the fourth quarter of 2018 and there can be no assurance that Maiden will declare and pay dividends on the Securities in the future. The Securities are perpetual and there is no fixed date on which Maiden is required to redeem or otherwise repurchase them. Further, given the perpetual form of capital the Securities represent, there can be no assurance that Maiden or the Company will make additional offers in the future to purchase the Securities.

The acquisition by the Company of the Securities pursuant to this Offer is being made in compliance with the Company’s investment policy which has been approved by the Vermont Department of Financial Regulation.

Maiden or the Company reserves the right, but is not obligated, to increase the Maximum Aggregate Purchase Amount in its sole and absolute discretion. The Offer will expire on December 15, 2020 at 11:59 p.m., New York City time, unless Maiden or the Company extends it (such time and date, as the same may be extended, the “Expiration Time”).

If the aggregate Offer Price of the Securities that are validly tendered and not properly withdrawn as of the Expiration Time (the “Total Consideration Amount”) exceeds the Maximum Aggregate Purchase Amount, the Company will accept for purchase that number of Securities that does not result in the Total Consideration Amount exceeding the Maximum Aggregate Purchase Amount. In that event, the Securities will be subject to proration, as described in the Offer to Purchase, dated November 13, 2020 (the “Offer to Purchase”).

The Company will pay the purchase price for the Securities it purchases promptly after the Expiration Time and the acceptance of the Securities for purchase. The date on which such payment is made is referred to as the “Settlement Date.” The Company currently expects the Settlement Date to be December 17, 2020.

Securities tendered pursuant to the Offer may be validly withdrawn at any time on or prior to the Expiration Time by following the procedures described in the Offer to Purchase.

The terms and conditions of the Offer are described in the Offer to Purchase. The Offer is subject to the satisfaction or waiver of certain conditions specified in the Offer to Purchase.

The Offer to Purchase will be mailed to record holders of the Securities and will be furnished to brokers, dealers, commercial banks, trust companies or other nominee stockholders and similar persons whose names, or the names of whose nominees, appear on Maiden’s shareholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing for subsequent transmittal to beneficial owners of the Securities. The Offer to Purchase contains important information that holders are urged to read before any decision is made with respect to the Offer.

Pursuant to Rule 13e-4(c)(2) under the Securities Exchange Act of 1934, as amended, Maiden will file with the Securities and Exchange Commission (the “SEC”) an Issuer Tender Offer Statement on Schedule TO, which contains additional information with respect to the Offer. The Schedule TO, including the exhibits and any amendments and supplements thereto, may be examined, and copies may be obtained, at the SEC’s website at www.sec.gov.

BofA Securities is acting as dealer manager for the Offer. The Company will pay registered brokers and dealers in the United States that process tenders into the Offer from DTC participants and persons resident in the United States (the “Retail Processing Dealers”) retail processing fees. Each Retail Processing Dealer that successfully processes tenders from a retail beneficial owner of Securities will be eligible to receive a retail processing fee from the Company equal to $0.125 per Series A Preference Share, Series C Preference Share or Series D Preference Share validly tendered and not properly withdrawn by or on behalf of such retail beneficial owner and accepted for purchase by the Company, except for any Series A Preference Shares, Series C Preference Shares or Series D Preference Shares tendered by a Retail Processing Dealer for its own account. For additional information regarding the terms of the Offer, please contact: BofA Securities, Attn: Liability Management, at telephone (980) 387-3907 (collect) or by email at [email protected]. To request documentation relating to the Offer, please contact Global Bondholder Services Corporation, which is acting as the tender agent and information agent for the Offer, at (866)-794-2200 (toll-free) or (212) 430-3774.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER OR SOLICITATION TO PURCHASE SECURITIES. THE OFFER IS BEING MADE SOLELY PURSUANT TO THE OFFER TO PURCHASE, WHICH SETS FORTH THE COMPLETE TERMS OF THE OFFER THAT HOLDERS OF THE SECURITIES SHOULD CAREFULLY READ PRIOR TO MAKING ANY DECISION.

THE COMPANY IS NOT MAKING THE OFFER TO (NOR WILL IT ACCEPT ANY TENDER OF SECURITIES FROM OR ON BEHALF OF) HOLDERS OF SECURITIES IN ANY JURISDICTION IN WHICH THE MAKING OF THE OFFER OR THE ACCEPTANCE OF ANY TENDER OF SECURITIES WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICTION. HOWEVER, THE COMPANY MAY, AT ITS DISCRETION, TAKE SUCH ACTION AS THE COMPANY MAY DEEM NECESSARY FOR IT TO MAKE THE OFFER IN ANY SUCH JURISDICTION AND EXTEND THE OFFER TO HOLDERS OF SECURITIES IN SUCH JURISDICTION. IN ANY JURISDICTION THE SECURITIES OR BLUE SKY LAWS OF WHICH REQUIRE THE OFFER TO BE MADE BY A LICENSED BROKER OR DEALER, THE OFFER SHALL BE DEEMED TO BE MADE ON THE COMPANY’S BEHALF BY ONE OR MORE REGISTERED BROKERS OR DEALERS WHICH ARE LICENSED UNDER THE LAWS OF SUCH JURISDICTION.

About Maiden Holdings, Ltd.

Maiden Holdings, Ltd. is a Bermuda-based holding company formed in 2007.

Forward-Looking Statements

This press release includes forward-looking statements. These statements are necessarily subject to risk and uncertainty and actual results could differ materially from those anticipated due to various factors, including those set forth from time to time in the documents filed or furnished by Maiden Holdings, Ltd. with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements and Maiden Holdings, Ltd. undertakes no obligation to update any such statements to reflect circumstances or events that occur after the date on which the forward-looking statement is made.

Sard Verbinnen & Co.

[email protected]

KEYWORDS: Bermuda Caribbean

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Posted on

Independent directors will integrate half of Lleida.net’s board

PR Newswire

MADRID, Nov. 13, 2020 /PRNewswire/ — Mr. Jorge Sainz de Vicuña was appointed today an independent director of Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF), at the recommendation of the CEO and founder of the company, Sisco Sapena.

With this appointment, half of Lleida.net board of directors is now formed by independent directors.

Until yesterday, Mr. Sainz de Vicuña held the position in the company as a proprietary director, representing the group of shareholders made up by Cántabro Catalana de Inversiones S.A., Empresa Nacional de Innovación (ENISA) and Sepi Desarrollo Empresarial (SEPIDES).

He resigned at the request of those funds, after having expired the pooling agreement for 21.27% of the shares which allowed his appointment.

Sainz de Vicuña’s appointment, which has been ratified by the Board of Directors, is recognition to his work in favor of the company.

“Jorge has been an important board member since Lleida.net started to trade in Paris and New York. His opinion is important for the company, and we are delighted that he will continue as a member of the board of directors”, explained Sapena, who founded the company in 1995. Previously, Jorge Sainz de Vicuña, was a proprietary director of Lleida.net between 2018 and 2020, in representation several reference shareholders.

He worked in Banco Santander, in management functions, and previously in Banco Español de Crédito and in Banesto’s Corporación Industrial y Financiera.

He has more than 25 years of experience in managing companies belonging to their respective industrial portfolios and to venture capital funds. 

He has carried out tasks in the fields of M&A, strategy, operations and financial restructuring in companies of various sectors and sizes.

He was CEO of Depósitos Portuarios and Galaxia Televisión, and a board member of the World Trade Center Barcelona, Advent España, Laparanza and Oildor, among others.

He has a degree in Economics, and Business Studies from the Colegio Universitario de Estudios Financieros (CUNEF) and a PDG from IESE.

Lleida.net is currently the leading European company in the eSignature industry.

Its services of notification and electronic contracting are recognized as valid before courts and public administrations in more than 75 countries.

The company has 187 patents in digital signature matters, which have been granted by more than 50 countries in the five continents, including the United States, the European Union, China, Russia, India, Mexico, Japan, Colombia, Argentina, Peru, South Africa, Nigeria, Australia or New Zealand.

Lleida.net started trading in the OTCQX Best Markets index in New York last week.

Contact:
The Paloma Project
Media, [email protected]  
+356-7946-7486

Cision View original content:http://www.prnewswire.com/news-releases/independent-directors-will-integrate-half-of-lleidanets-board-301172977.html

SOURCE Lleida.net

Posted on

Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation

Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited “mini-tender” offer dated November 9, 2020, made by TRC Capital Investment Corporation, an Ontario, Canada, corporation to purchase up to 1,000,000 shares of Vertex common stock. TRC Capital’s unsolicited “mini-tender” offer price of $210.00 per share is approximately 4.67% below the $220.28 per share closing price of Vertex’s common stock on November 6, 2020, the last trading day prior to the commencement of the offer.

Vertex does not endorse TRC Capital’s offer and recommends that Vertex shareholders reject the offer and not tender their shares in response to TRC Capital’s unsolicited offer. The “mini-tender” offer is at a price below the market price of shares of Vertex’s common stock (as of today’s date) and is subject to numerous conditions, including TRC Capital’s ability to obtain financing necessary to consummate the offer. Vertex is not affiliated in any way with TRC Capital, the offer, or the offer documentation.

TRC Capital has made many similar “mini-tender” offers for the shares of other companies. “Mini-tender” offers are designed to seek less than five percent of a company’s outstanding shares, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (SEC) because they are below the SEC’s threshold to provide such disclosure and procedural protections for investors.

The SEC has cautioned investors about “mini-tender” offers in an investor alert. The SEC noted that these offers “have been increasingly used to catch investors off guard” and that many investors who hear about “mini-tender” offers “surrender their securities without investigating the offer, assuming that the price offered includes the premium usually present in larger, traditional tender offers.”

To read more about the risks of “mini-tender” offers, please review the alert on the SEC’s website at http://www.sec.gov/investor/pubs/minitend.htm.

Like TRC Capital’s other offers, this “mini-tender” puts individual investors at risk because they may sell their shares at a discount without so realizing. Vertex urges shareholders to obtain current stock quotes for their shares of Vertex common stock, review the terms and conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC Capital’s “mini-tender” offer. Shareholders who have already tendered should consider the advisability of withdrawing their shares as permitted under TRC Capital’s Offer to Purchase documents.

Shareholders who have already tendered their shares may withdraw them at any time prior to the expiration of the offer, and if TRC Capital has not accepted a shareholder’s shares for payment pursuant to the offer, that shareholder may withdraw them at any time after December 21, 2020, until TRC Capital accepts the shareholder’s shares for payment, in accordance with TRC Capital’s offering documents.. According to the offer documents, the offer is currently scheduled to expire at 12:01 a.m., New York City time, on December 9, 2020.

Vertex encourages broker-dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer “mini-tender” offer dissemination and disclosure at https://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm and the NASD Notice to Members regarding guidance to members forwarding “mini-tender” offers to their customers, which can be found at https://www.finra.org/sites/default/files/NoticeDocument/p004221.pdf.

Vertex requests that a copy of this news release be included with all distributions of materials relating to TRC Capital’s “mini-tender” offer related to shares of Vertex’s common stock.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated

Investors:

[email protected]

or

617-961-7163

Media:

[email protected]

or

U.S.: 617-341-6992

or

International: +44 20 3204 5275

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Diabetes Genetics Pharmaceutical Cardiology Biotechnology

MEDIA:

Logo
Logo
Posted on

Taat Producing 600 lb / 272 kg of Beyond Tobacco™ Per Day, Increased Capacity from Upgraded Equipment can Provide Material for up to 2.1 Million Taat Cartons Per Year

After beginning large-scale in-house production of Taat’s Beyond Tobacco™ base material, the Company has already reached 50% of its production capacity even before launching. Each 16-hour day of production yields approximately 600 lb / 272 kg of Beyond Tobacco™, which is sufficient to produce one full 1,440-carton pallet of Taat. Based on current volumes, the Company has procured new machinery to be installed in its Las Vegas, NV processing facility which is expected to increase production bandwidth to as much as
2,400 lb / 1,088 kg per day
. Additionally, the Company’s CEO Setti Coscarella has released an informational video statement in which Mr. Coscarella details the weaknesses of mainstream alternatives to tobacco cigarettes, and explains how Taat is being developed and commercialized to address these shortcomings.

LAS VEGAS and VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) is pleased to announce that its in-house production of the Beyond Tobacco™ base material for Taat, its flagship product to be launched in Ohio later this month, is now being produced at a rate of approximately 600 lb / 272 kg per day, a quantity that is sufficient to produce approximately one full 1,440-carton pallet of Taat. As stated in the Company’s press release dated October 16, 2020, Taat’s Las Vegas, NV processing facility can produce up to 1,200 lb / 544 kg of Beyond Tobacco™ per day. Having already reached 50% of its in-house production capacity for Beyond Tobacco™ even before launching Taat, the Company has ordered upgraded machinery to accommodate forecasted increases in demand following the debut of Taat in the United States. In addition to current interest in Taat from tobacco wholesalers and retailers in Ohio, nearly one third of unique visitors to the Company’s TryTaat landing page (http://trytaat.com) have requested Taat product samples. With Taat’s Ohio launch set to occur later this quarter, the Company’s Las Vegas, NV processing facility has been in operation for 16 hours per day every day including weekends to prepare a sufficient supply of Beyond Tobacco™ to meet anticipated demand.

The Company has developed Beyond Tobacco™ to taste, smell, and burn similarly to tobacco, despite containing no tobacco or nicotine. Beyond Tobacco™ is the base material of Taat, an alternative to traditional cigarettes offered in a cigarette-style format in Original, Smooth, and Menthol varieties. Under executive leadership with “Big Tobacco” pedigree, the Company has chosen the state of Ohio as the launch market for Taat in the United States, where an initial supply of Taat intended for sale at retail will arrive in Ohio later in Q4 2020. The Beyond Tobacco™ base material is processed in the Company’s Las Vegas, NV facility with a 14-step refinement procedure. Finished Beyond Tobacco™ is then sent to the Company’s contract manufacturer, who also makes cigarettes for national and global brands, for production and warehousing before shipment to wholesalers.

Beginning in mid-November 2020, deliveries of upgraded machinery for producing Beyond Tobacco™ will begin to arrive at the Company’s Las Vegas, NV processing facility. The new equipment, which includes conveyor belts and a vacuum sealer, is expected to increase Taat’s daily production capacity of Beyond Tobacco™ to a maximum of 2,400 lb / 1,088 kg per 16-hour day. Based on current Taat manufacturing yields, the Company anticipates this greater production bandwidth for Beyond Tobacco™ will allow for more than 2.1 million ten-pack cartons of Taat to be made on an annual basis. At this time, the Company is continuing to produce approximately 600 lb / 272 kg of Beyond Tobacco™ per day until it establishes a supply of material sufficient to produce approximately 30 pallets (43,200 cartons) of Taat.

Taat Herb Co. Founder Joe Deighan in front of the Company’s facility in Las Vegas, NV, where the Beyond Tobacco™ base material is produced.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/50fd3780-4d57-4233-b1dc-c67e5816af08

Readers using news aggregation services may be unable to view the media above. Please access the

Investor Relations

section of the Company’s website for a version of this press release containing all published media.

The Company is also pleased to release an informational video statement made by its Chief Executive Officer Setti Coscarella, in which Mr. Coscarella details the weaknesses of mainstream products positioned as alternatives to tobacco cigarettes, and explains how Taat has been developed to address such weaknesses. Based on positive feedback from investors and the general public regarding Taat’s proprietary video content, the Company intends to continue releasing informational videos from its management team and advisory board on its YouTube channel.

Taat CEO Setti Coscarella in the Company’s latest informational video statement, which can be viewed by clicking the thumbnail above or


clicking here


.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ed733b4e-968a-46b3-8fe1-eaf7e74cb200

Readers using news aggregation services may be unable to view the media above. Please access the

Investor Relations

section of the Company’s website for a version of this press release containing all published media.

Taat Herb Co. Founder Joe Deighan, who directly oversees the Company’s Las Vegas, NV processing facility operations, said “It’s very exciting to be playing a firsthand role in developments such as these as we bring the Taat vision to reality on such a large scale. As intense as it may be to lead non-stop production of Beyond Tobacco™ for 16 hours per day every day, this is a major turning point in our journey to launch. We already have the market-ready product formulation, the distribution reach, and the go-to-market plan. What we need now is inventory to meet anticipated demand, and the fact that the supply we’re producing today has a clear path to being placed on retail shelves among incumbent tobacco products soundly validates that we are now far past the initial R&D phase and well into the ‘doing business’ phase.”

Taat Chief Executive Officer Setti Coscarella commented, “With the amount of interest Taat has been getting from tobacco wholesalers and individual adult smokers from around the world, as well as thousands of free sample requests in the United States on our TryTaat landing page, it is no secret at all that quantity is now the name of the game in order to meet potential demand. This comes as no surprise considering how rapidly Taat sold out during early-stage retail market testing earlier this year. Accordingly, we have taken it upon ourselves to maximize output of Beyond Tobacco™ from our Las Vegas processing facility by operating two daily shifts instead of one, and upgrading our equipment to improve our production capacity. As I mentioned in the latest informational video, Taat is very unique in that it offers exactly what other alternatives to tobacco cigarettes cannot offer. Even before we’ve launched, smokers of legal age all across the United States have recognized this, which is why we are seeking to maximize our production capacity now. I look forward to seeing the performance of our upgraded equipment as we ramp up production of Beyond Tobacco™ to prepare for our launch in Ohio.”

On behalf of the Board of Directors of the Company,

TAAT LIFESTYLE & WELLNESS LTD.

“Setti Coscarella”

Setti Coscarella, CEO

For further information, please contact:

Taat Investor Relations
1-833-TAAT-USA (1-833-822-8872)
[email protected]

THE CANADIAN SECURITIES EXCHANGE (CSE) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

About Taat Lifestyle & Wellness Ltd.

The Company has developed Taat, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. Taat’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, Taat is launching in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion1 global tobacco industry.

For more information, please visit http://taatusa.com.

References

1

British American Tobacco – The Global Market

Forward Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the potential launch of Beyond Tobacco™, in addition to the following: Potential outcomes from planned upgrades to Taat’s production facility equipment. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.

This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.

Statement Regarding Third-Party Investor Relations Firms

Disclosures relating to investor relations firms retained by Taat Lifestyle & Wellness Ltd. can be found under the Company’s profile on http://sedar.com.



Posted on

Bespoke Capital Acquisition Corp. Reports Third Quarter 2020 Financial Results

Canada NewsWire

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES/

TORONTO, Nov. 13, 2020 /CNW/ – Bespoke Capital Acquisition Corp. (TSX: BC.U) (TSX: BC.WT.U) (“BCAC“) is reporting its financial results for the interim period ending September 30, 2020. BCAC’s unaudited interim financial statements have been filed on the System for Electronic Document Analysis and Retrieval (“SEDAR“) and may be viewed by shareholders and interested parties under BCAC’s profile on SEDAR at www.sedar.com.

About Bespoke Capital Acquisition Corp.
Bespoke Capital Acquisition Corp. is a special purpose acquisition corporation incorporated under the laws of the Province of British Columbia for the purpose of effecting, directly or indirectly, a qualifying acquisition within a specified period of time.

SOURCE Bespoke Capital Acquisition Corp.

Posted on

Amgen To Present At The Jefferies Virtual London Healthcare Conference

PR Newswire

THOUSAND OAKS, Calif., Nov. 13, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at the Jefferies Virtual London Healthcare Conference at 12:00 p.m. ET on Wednesday, Nov. 18, 2020. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

About Amgen
 

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631(media) 
Arvind Sood, 805-447-1060 (investors) 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-jefferies-virtual-london-healthcare-conference-301172939.html

SOURCE Amgen

Posted on

QEBR to Refocus on Medical CBD

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — Virtual Medical International Inc. (OTC: QEBR) today announced that it is returning to its medical roots by entering the Medical Grade CBD oil business.

“The majority shareholder has determined that it is in the best interest of all of the shareholders to repurpose the company’s strategy to take advantage of the important medical needs of millions of adults across the globe for which this product has the proven capability to relieve needless suffering,” reported Jun Liang, Board Member.

As a result of this change of business, Larry Eastland has resigned as CEO.  A new CEO will be announced shortly.

This will also result in QEBR exiting the Crypto currency hosting business which has proven to be a challenging and costly business for QEBR.

About QEBR:
QEBR is the trading symbol for Virtual Medical International, Inc., a Nevada corporation.

Forward-Looking Statements
Legal Notice Regarding Forward-Looking Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined, and assumptions of management. Forward looking statements are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur.

Actual results may differ materially from those currently anticipated due to a number of factors beyond the reasonable control of the Company. It is important to note that actual outcomes and the Company’s actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include misinterpretation of data, the Company’s ability to raise financing for operations, breach by parties with whom we have contracted, and the possible inability to maintain qualified employees or consultant

For more information please see our website: http://www.qebr.net
Contact: [email protected]
Source: Jun Liang, QEBR Chief Technology Officer

Cision View original content:http://www.prnewswire.com/news-releases/qebr-to-refocus-on-medical-cbd-301172965.html

SOURCE QEBR

Posted on

BABA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Alibaba Group Holding Limited

BABA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Alibaba Group Holding Limited

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Ciccarello v. Alibaba Group Holding Limited, et al., (Case No. 1:20-cv-09568) onbehalf of persons and entities that purchased or otherwise acquired Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) securities between October 21, 2020 and November 3, 2020, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.

If you suffered a loss on your Alibaba investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/alibaba-group-holding-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] or visit our website at www.glancylaw.com to learn more about your rights.

Alibaba is an online and mobile commerce company. Alibaba owns a 33% equity interest in Ant Small and Micro Financial Services Group Co., Ltd. (“Ant Group”), a financial technology company that is best known for operating Alipay, one of the largest mobile and online payments platforms.

On July 20, 2020, Ant Group announced that it had begun the process of a concurrent initial public offering (“IPO”) on the Shanghai and Hong Kong stock exchanges.

On October 26, 2020, Ant Group priced its IPO and was set to raise $34.5 billion, making it the largest public offering in history.

On November 2, 2020, Financial Times reported that Chinese regulators had met with Ant Group’s controller Jack Ma, executive chairman Eric Jing, Chief Executive Officer Simon Hu. The article stated that, though regulators did not provide details, “the Chinese word used to describe the interview – yuetan – generally indicates a dressing down by authorities.” The article also included a statement from Ant Group that it will “implement the meeting opinions in depth.”

On November 3, 2020, the IPO was suspended because Ant Group “may not meet listing qualifications or disclosure requirements due to material matters” related to the meeting with regulators the previous day and “the recent changes in the Fintech regulatory environment.”

On this news, the Company’s share price fell $25.27, or 8%, to close at $285.57 per share on November 3, 2020, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Ant Group did not meet listing qualifications or disclosure requirements for certain material matters; (2) that certain impending changes in the Fintech regulatory environment would impact Ant Group’s business; (3) that, as a result of the foregoing, Ant Group’s IPO was reasonably likely to be suspended; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Alibaba’s securities during the Class Period, you may move the Court no later than 60 days from the date of this notice toask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Maiden Holdings, Ltd. Releases Third Quarter 2020 Earnings

Maiden Holdings, Ltd. Releases Third Quarter 2020 Earnings

HAMILTON, Bermuda–(BUSINESS WIRE)–
Maiden Holdings, Ltd. (NASDAQ:MHLD) has released its third quarter 2020 financial results via its investor relations website at https://www.maiden.bm/investor_relations.

About Maiden Holdings, Ltd.

Maiden Holdings, Ltd. is a Bermuda-based holding company formed in 2007.

Sard Verbinnen & Co.

[email protected]

KEYWORDS: Bermuda Caribbean

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA: